Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study.
TL;DR: Early results on the toxicity and efficacy of the combination of hypofractionated IG-IMRT and low-dose-rate brachytherapy boost are favorable, and longer follow-up is needed to confirm safety and effectiveness.
Journal ArticleDOI
Лучевая терапия рака предстательной железы
А. Д. Каприн,Е. В. Хмелевский,А. Г. Зубовская,К. М. Нюшко,Andrey Kaprin,E. V. Khmelevsky,A. G. Zubovskaya,K. M. Nyushko +7 more
Journal ArticleDOI
Acute toxicity after hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer
Frank Lohr,Michael Ehmann +1 more
TL;DR: In this paper, the authors show that kumulative Inzidenzen jedes Toxizitätstyps nicht mehr als 8 % höher in der Hypofraktionierungsgruppe als bei Standardfraktionierschräterung sind.
Journal ArticleDOI
Safety of stereotactic body radiation therapy for localized prostate cancer without treatment planning MRI
K. Amarell,Anna Jaysing,Christian Mendez,J A Haas,Seth Blacksburg,Aaron E. Katz,Astrid Sanchez,Angela Tong,Todd C. Carpenter,Matthew Witten,Sean P. Collins,Jonathan W. Lischalk +11 more
TL;DR: The use of treatment planning prostate MRI for Stereotactic Body Radiation Therapy (SBRT) is largely a standard, yet not all patients can receive MRI for a variety of clinical reasons as discussed by the authors .
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more